Cedars-Sinai Cancer Health System: Precision Medicine in Oncology

Sat, July 16, 2022 - Sat, July 16, 2022

8:00 AM - 12:05 PM

Online

<add text, as needed>

**CLICK ON THE LINK BELOW TO COMPLETE AN EVALUATION AND CLAIM CME CREDIT.**

[insert Attestation form link using format: [https://cedars.cloud-cme.com/Form.aspx?FormID=####](https://cedars.cloud-cme.com/Form.aspx?FormID=) ]

**Once you click on the link, you will be prompted to log-in or create an account in the CME Portal.**

### POLICY ON DISCLOSURE:

Cedars-Sinai adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). The following was reported. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Name of Ineligible Company(s) / Nature of Relationship(s)** |
| Robert A Figlin, MD | Course Director, Faculty | Nothing to disclose - 06/17/2022 |
| Dan Theodorescu, MD, PhD | Course Director, Faculty | Nothing to disclose - 06/14/2022 |
| Warren Tourtellotte, MD, PhD | Course Director, Faculty | Nothing to disclose - 07/12/2022 |
| Grant Dagliyan, PhD | Faculty | Nothing to disclose - 05/31/2022 |
| Andrew E Hendifar, MD | Faculty | Nothing to disclose - 07/08/2022 |
| John E. Lee, MS, LCGC | Faculty | Nothing to disclose - 10/21/2021 |
| Dermot McGovern, MD, PhD | Faculty | Consultant-Prometheus Biosciences|Consultant-Prometheus Laboratories|Stock Options or Shareholder-Prometheus Biosciences|Consultant-Takeda Pharmaceuticals, Inc.|Consultant-Palatin|Consultant-Pfizer, Inc. (Relationship has ended) - 02/17/2022 |
| Monica M. Mita, MD | Faculty | Nothing to disclose - 06/03/2022 |
| Sukhmani Padda, MD | Faculty | PrincipalNamedInvestigator-Epicentrx (Relationship has ended)|PrincipalNamedInvestigator-Bayer Corporation (Relationship has ended)|PrincipalNamedInvestigator-Boehringer Ingelheim Vetmedica GmbH (Relationship has ended)|Advisor-Janssen Pharmaceuticals|Advisor-Sanofi-Aventis|Advisor-Mirati Therapeutics|Speaker-OncLive (Relationship has ended)|Consultant-Jazz Pharmaceuticals (Relationship has ended)|Consultant-Physician Education Resource (PER) (Relationship has ended)|Advisor-Genentech, Inc. (Relationship has ended)|Independent ContractorResearcher-Nanobiotix (Relationship has ended)|Advisor-AstraZeneca|Advisor-G1 Therapeutics (Relationship has ended)|Advisor-Blueprint (Relationship has ended)|Speaker-California Consortium/MECC Global Meetings (Relationship has ended) - 11/04/2021 |
| Sarah Parker | Faculty | Nothing to disclose - 07/08/2022 |
| Manali Patel, MD | Faculty | Nothing to disclose - 05/25/2022 |
| Edwin Posadas, MD | Faculty | PrincipalNamedInvestigator-Pfizer, Inc. - 10/26/2021 |
| Eric Vail, MD | Faculty | Speaker-Bayer Corporation|Speaker-Eli Lilly and Company|Speaker-Johnson and Johnson|Speaker-AstraZeneca|Consultant-PierianDx|Consultant-Thermo Fisher Scientific|Consultant-Illumina|Speaker-Tempus|Independent ContractorResearcher-LungLifeAI - 06/17/2022 |
| Katelyn Atkins, MD, PhD | Faculty, Other Planning Committee Member | Nothing to disclose - 07/12/2022 |

### ACCREDITATION STATEMENT:

Cedars-Sinai Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### CREDIT DESIGNATION STATEMENT:

Cedars-Sinai Medical Center designates this Live Activityfor a maximum of **3.50** *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### NON-PHYSICIAN ATTENDANCE

Participation credit will be provided to other health care professionals via your CME Portal transcript. Participants should ensure in advance that their credentialing or licensing organization accepts AMA PRA Category 1 Credits™.